Information  X 
Enter a valid email address

Syncona Limited (SYNC)

  Print      Mail a friend

Thursday 18 July, 2019

Syncona Limited

Issue of shares per 2019 dividend & PDMR dealings

RNS Number : 0316G
Syncona Limited
18 July 2019
 

Syncona Limited

 

Issue of shares pursuant to the 2019 dividend and PDMR dealings

 

18 July 2019

 

Syncona Limited (the "Company") today announces that a total of 860,090 new ordinary shares will be issued in satisfaction of the payment of the Company's 2019 dividend to those qualifying shareholders who did not elect to receive the dividend in cash.  The new ordinary shares, when issued, will rank pari passu with the existing issued ordinary shares of the Company. 

 

Application has been made to the Financial Conduct Authority for the shares to be admitted to the Official List, and to the London Stock Exchange for the shares to be admitted to trading and it is expected that dealings will commence in the new ordinary shares on 29 July 2019.

 

Notification of transactions by Persons Discharging Managerial Responsibilities ("PDMRs") are set out below.

 

[ENDS]

 

Enquiries

 

Syncona Ltd

Siobhan Weaver / Annabel Clay

Tel: +44 (0) 20 3981 7940

 

FTI Consulting

Brett Pollard / Natalie Garland-Collins

Tel: +44 (0) 20 3727 1000

Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com  

About Syncona:

 

Syncona is a leading FTSE250 healthcare company focused on investing in and building global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

 

We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses.

 

We take a long-term view, underpinned by a deep pool of capital, and are established leaders in the development of genetic medicine, particularly gene and cell therapy. We focus on delivering dramatic efficacy for patients in areas of high unmet need.

 

1.

Details of PDMR / person closely associated with them ("PCA")

a)

Name

Martin Murphy

b)

Position / status

Chief Executive Officer, SIML

c)

Initial notification / amendment

Initial Notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary shares 

GG00B8P59C08

b)

Nature of the transaction

Acquisition of shares under the 2019 Dividend

c)

Price(s) and volume(s)

Price(s)

Volume(s)

2.281

3,094

d)

Aggregated information

Aggregated volume

Price

 

 

N/A

e)

Date of the transaction

18 July 2019

f)

Place of the transaction

Outside a trading venue

g)

Currency

GBP - British Pound

 

1.

Details of PDMR / person closely associated with them ("PCA")

a)

Name

Jeremy Tigue

b)

Position / status

Chairman

c)

Initial notification / amendment

Initial Notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary shares 

GG00B8P59C08

b)

Nature of the transaction

Acquisition of shares under the 2019 Dividend

c)

Price(s) and volume(s)

Price(s)

Volume(s)

2.281

4,820

d)

Aggregated information

Aggregated volume

Price

 

 

N/A                                                      

e)

Date of the transaction

18 July 2019

f)

Place of the transaction

Outside a trading venue

g)

Currency

GBP - British Pound

 

1.

Details of PDMR / person closely associated with them ("PCA")

a)

Name

Ellen Strahlman

b)

Position / status

Non-Executive Director

c)

Initial notification / amendment

Initial Notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary shares 

GG00B8P59C08

b)

Nature of the transaction

Acquisition of shares under the 2019 Dividend

c)

Price(s) and volume(s)

Price(s)

Volume(s)

2.281

1,584

d)

Aggregated information

Aggregated volume

Price

 

 

N/A

e)

Date of the transaction

18 July 2019

f)

Place of the transaction

Outside a trading venue

g)

Currency

GBP - British Pound

 

1.

Details of PDMR / person closely associated with them ("PCA")

a)

Name

Robert Hutchinson

b)

Position / status

Non-Executive Director

c)

Initial notification / amendment

Initial Notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary shares 

GG00B8P59C08

b)

Nature of the transaction

Acquisition of shares under the 2019 Dividend

c)

Price(s) and volume(s)

Price(s)

Volume(s)

2.281

432

d)

Aggregated information

Aggregated volume

Price

 

 

N/A

e)

Date of the transaction

18 July 2019

f)

Place of the transaction

Outside a trading venue

g)

Currency

GBP - British Pound

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
IOELLFSSDAITLIA

a d v e r t i s e m e n t